Madrigal Pharma (MDGL) Misses Q3 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.34), $0.44 worse than the analyst estimate of ($4.90). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight